Lilly's Chief Scientific Officer: 'We have an obligation to go after big problems'
Eli Lilly's Chief Scientific Officer Dan Skovronsky says the company wants to take big swings in Alzheimer's, ALS, chronic ...
New weight loss drugs aim to save muscle
About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...
Lilly Sells $6.5 Billion of Bonds for Cancer Drug Purchase
Eli Lilly & Co. tapped the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of a ...
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in ...
Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.
The Motley Fool6 天
Think Eli Lilly's Stock Is Expensive? Here's Why Selling It Now Could Be a Huge Mistake
For years, Eli Lilly has been generating solid growth numbers -- but lately, they've been accelerating rapidly. The company is coming off a solid quarter where its revenue rose by 45% for the last ...
Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall short
Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soared. The company's quarterly earnings topped ...
NBC New York15 天
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in ...
That appears to have more potent effects on a person's appetite and satisfaction with food than other treatments. Tirzepatide, the active ingredient in Eli Lilly's weight loss shot Zepbound and ...